V-161: A Breakthrough in the Fight against Antibiotic-Resistant VRE Infections

V-161 targets a crucial enzyme in VRE, offering promise in combating antibiotic-resistant infections in hospital environments

V-161, a novel compound targeting the Na+-V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization. A recent study has demonstrated a promising approach for fighting antibiotic resistance by identifying a compound, V-161, that inhibits a sodium-pumping enzyme critical for VRE survival under alkaline conditions in the intestine while preserving beneficial bacteria. This breakthrough offers hope for treating hospital infections and tackling the global threat of antibiotic-resistant bacteria.

Researchers from Japan have identified V-161, a compound that inhibits Enterococcus hirae V-ATPase activity, disrupting Na+ transport and effectively inhibiting VRE growth

Please refer to the press release for details.